

| То:      | Kaiser Permanente Network Physicians  | Date:                                      | March 7, 2024   |
|----------|---|--|---|
| Subject: | Notice to MD's: Network Provider Notification<br>of Part D Negative Formulary Change 2024 | From:<br>Location:<br>Phone:<br>Copies to: | Neelashi Okahde, MD<br>Maisha Draves, MD<br>Anne Tran-Pugh, Pharm.D.<br>Drug Intelligence & Strategy<br>Independence Park, Downey<br>562/658-3630<br>Sonia Boothe, PharmD<br>Abdul Ghorbandi, PharmD<br>Utsav Patel, PharmD<br>Jennifer Cashman, PharmD<br>Jocelyn Chan, PharmD |

As a part of our due diligence to inform all concerned of Medicare Part D Formulary Changes, the following notification is requested by CMS to be sent to all Providers.

## Medicare Part D Benefit Coverage – Product removal

During the year, Kaiser Permanente may make changes to our Medicare Part D Formulary (Drug List). As a participating Network Provider in the Kaiser Permanente Part D program, the list below is intended to inform you of these changes.

## Product Removal: VASCEPA CAPS 0.5GM AND 1 GM

Effective April 1, 2024, the brand-name drug Vascepa Caps 0.5 GM and 1 GM will be removed from our Drug List. We will add a new generic version of the brand-name drug to the Drug List (it is called losapent Ethyl Caps 0.5 GM and 1 GM).

Affected members who were prescribed these drugs prior to each effective date will be grandfathered, meaning members will continue to receive the removed product under their Part D benefit and continue to receive the product, except for members who have been converted to the generic alternatives.

The following table lists all products recently changed from the Medicare Part D Formulary.

| Reason for change | Drug<br>Name/Description     | Date and Type of<br>Change:                                | Alternate Drug<br>(Note: Over-the-counter (OTC) drugs are<br>not covered under the Medicare Part D<br>benefit) |
|-------------------|------------------------------|--|--|
| Generic Available | VASCEPA CAPS<br>0.5 GM, 1 GM | April 1, 2024<br>Brand drug to be<br>replaced with generic | ICOSAPENT ETHYL CAPS 0.5 GM, 1<br>GM   |
| Generic Available | LIALDA TBEC 1.2<br>GM        | March 1, 2024<br>Brand drug to be<br>replaced with generic | MESALAMINE TBEC 1.2 GM   |
| Generic Available | VOTRIENT TABS<br>200 MG      | February 1, 2024<br>Brand drug to be                       | PAZOPANIB HCL TABS 200 MG  |



|                   |                                   | replaced with generic |   |
|-------------------|-----------------------------------|-----------------------|---|
| Generic Available | SYMBICORT AERO<br>80-4.5 MCG/ACT, | February 1, 2024      | BREYNA AERO 80-4.5 MCG/ACT, 160-<br>4.5 MCG/ACT |
|                   | 160-4.5 MCG/ACT                   | Brand drug to be      |   |
|                   |                                   | replaced with generic |   |